MET gene alterations predict poor survival following chemotherapy in patients with advanced cancer

MET gene alterations predict poor survival following chemotherapy in patients with advanced cancer

Background: To aid in oncology drug development, we investigated MET proto-oncogene receptor tyrosine kinase gene aberrations in 2,239 oncology patients who underwent next-generation sequencing (NGS) in clinical practice.Materials and methods: From November 2019 to January 2021, 2,239 patientswith a...

Full description

Bibliographic Details
Main Authors:	Jihoon Ko, Jaeyun Jung, Seung Tae Kim, Jung Yong Hong, Sehhoon Park, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Soomin Ahn, Kyoung-Mee Kim, Won Ki Kang, Jeeyun Lee
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-11-01
Series:	Pathology and Oncology Research
Subjects:	next-generation sequencing oncogene overall survival analysis MET MET alterations chemotherapy
Online Access:	https://www.por-journal.com/articles/10.3389/pore.2022.1610697/full

Similar Items

Clinical Implication of Concurrent Amplification of MET and FGFR2 in Metastatic Gastric Cancer
by: Seonggyu Byeon, et al.
Published: (2023-11-01)

Molecular Engineering Strategies Tailoring the Apoptotic Response to a MET Therapeutic Antibody
by: Chiara Modica, et al.
Published: (2020-03-01)

Prognosis and Concurrent Genomic Alterations in Patients With Advanced NSCLC Harboring MET Amplification or MET Exon 14 Skipping Mutation Treated With MET Inhibitor: A Retrospective Study
by: Li Liu, et al.
Published: (2021-06-01)

hOA-DN30: a highly effective humanized single-arm MET antibody inducing remission of ‘MET-addicted’ cancers
by: Ilaria Martinelli, et al.
Published: (2022-03-01)

Efficacy of CAR-T immunotherapy in MET overexpressing tumors not eligible for anti-MET targeted therapy
by: Cristina Chiriaco, et al.
Published: (2022-10-01)

MET in Non-Small-Cell Lung Cancer (NSCLC): Cross ‘a Long and Winding Road’ Looking for a Target
by: Gianluca Spitaleri, et al.
Published: (2023-09-01)

MET Expression Level in Lung Adenocarcinoma Loosely Correlates with <i>MET</i> Copy Number Gain/Amplification and Is a Poor Predictor of Patient Outcome
by: Wei Yin, et al.
Published: (2022-05-01)

MET-Targeting Anticancer Drugs—De Novo Design and Identification by Drug Repurposing
by: Kenneth Kin-Wah To, et al.
Published: (2023-07-01)

MET fusions are targetable genomic variants in the treatment of advanced malignancies
by: Dantong Sun, et al.
Published: (2024-01-01)

Non‐small cell lung cancer with mesenchymal–epithelial transition gene exon 14 skipping mutation treated with crizotinib
by: Seigo Katakura, et al.
Published: (2019-10-01)

MET Activation and Physical Dynamics of the Metastatic Process: The Paradigm of Cancers of Unknown Primary Origin
by: Giulia M. Stella, et al.
Published: (2017-10-01)

Therapeutic Efficacy of ABN401, a Highly Potent and Selective MET Inhibitor, Based on Diagnostic Biomarker Test in <i>MET</i>-Addicted Cancer
by: Jooseok Kim, et al.
Published: (2020-06-01)

Overview of Molecular Detection Technologies for <i>MET</i> in Lung Cancer
by: Carina Heydt, et al.
Published: (2023-05-01)

The German Priority Program SPP 1276 “Multiple Scales in Fluid Mechanics and Meteorology” (MetStröm)
by: Rupert Klein, et al.
Published: (2014-09-01)

Efficacy of first‐line immune checkpoint inhibitors in patients with advanced NSCLC with KRAS, MET, FGFR, RET, BRAF, and HER2 alterations
by: Yuji Uehara, et al.
Published: (2022-06-01)

Research Progresses in the Treatment of NSCLC with MET Gene Variants: A Riview
by: Ran CHEN, et al.
Published: (2022-12-01)

Responses to the Tepotinib in Gastric Cancers with MET Amplification or MET Exon 14 Skipping Mutations and High Expression of Both PD-L1 and CD44
by: Sung-Hwa Sohn, et al.
Published: (2022-07-01)

Increased expression of mRNA specific for c-Met oncogene in human papillary thyroid carcinoma
by: Anna Cyniak-Magierska, et al.
Published: (2007-03-01)

Gumarontinib in patients with non-small-cell lung cancer harbouring MET exon 14 skipping mutations: a multicentre, single-arm, open-label, phase 1b/2 trialResearch in context
by: Yongfeng Yu, et al.
Published: (2023-05-01)

Role and Therapeutic Targeting of the HGF/MET Pathway in Glioblastoma
by: Nichola Cruickshanks, et al.
Published: (2017-07-01)

Companion Diagnostics and Predictive Biomarkers for MET-Targeted Therapy in NSCLC
by: Jan Trøst Jørgensen, et al.
Published: (2022-04-01)

Phase II, open-label, multicenter trial of crizotinib in Japanese patients with advanced non-small cell lung cancer harboring a MET gene alteration: Co-MET study
by: Mototsugu Shimokawa, et al.
Published: (2020-03-01)

Partial treatment response to capmatinib in MET-amplified metastatic intrahepatic cholangiocarcinoma: case report & review of literature
by: Daniel S Lefler, et al.
Published: (2022-12-01)

Expression of c-MET in Invasive Meningioma
by: Sumi Yun, et al.
Published: (2015-01-01)

Longitudinal Plasma Proteomics-Derived Biomarkers Predict Response to MET Inhibitors for MET-Dysregulated NSCLC
by: Guang-Ling Jie, et al.
Published: (2023-01-01)

An Observatory for the <i>MET</i> Oncogene: A Guide for Targeted Therapies
by: Dogus M. Altintas, et al.
Published: (2023-09-01)

Tackling CASMI 2012: Solutions from MetFrag and MetFusion
by: Steffen Neumann, et al.
Published: (2013-08-01)

Programmed Cell Death Protein 1 Inhibitors and MET Targeted Therapies in NSCLC With MET Exon 14 Skipping Mutations: Efficacy and Toxicity as Sequential Therapies
by: Sally C.M. Lau, MD, MPH, et al.
Published: (2023-10-01)

MET and Small-Cell Lung Cancer
by: Francesco Gelsomino, et al.
Published: (2014-10-01)

Targeting <i>MET</i> Amplification: Opportunities and Obstacles in Therapeutic Approaches
by: Yuichi Kumaki, et al.
Published: (2023-09-01)

The PSI Domain of the MET Oncogene Encodes a Functional Disulfide Isomerase Essential for the Maturation of the Receptor Precursor
by: Dogus Murat Altintas, et al.
Published: (2022-10-01)

Development of metastatic poorly differentiated thyroid cancer from a sub-centimeter papillary thyroid carcinoma in a young patient with a germline MET mutation – association or random chance?
by: Klara Johansson, et al.
Published: (2021-08-01)

Association Between c-Met and Lymphangiogenic Factors in Patients With Colorectal Cancer
by: Han Jo Kim, et al.
Published: (2018-04-01)

The role of HGF/c-MET signaling pathway in lymphoma
by: Bao Quoc Lam, et al.
Published: (2016-12-01)

Cyclic Peptide-Based Biologics Regulating HGF-MET
by: Hiroki Sato, et al.
Published: (2020-10-01)

Long-term efficacy of crizotinib in a metastatic papillary renal carcinoma with MET amplification: a case report and literature review
by: Philippe Rochigneux, et al.
Published: (2018-11-01)

Combination therapy with c-met inhibitor and TRAIL enhances apoptosis in dedifferentiated liposarcoma patient-derived cells
by: Eun Byeol Jo, et al.
Published: (2019-05-01)

Dramatic intracranial response to tepotinib in a patient with lung adenocarcinoma harboring MET exon 14 skipping mutation
by: Shinkichi Takamori, et al.
Published: (2021-03-01)

Expert Consensus on Targeted Therapy of NSCLC with MET Exon 14  Skipping Mutation
by: Lung Cancer Specialty Committee of Chinese Elderly Health Care Association
Published: (2023-06-01)

Metabolic Profile Reveals the Immunosuppressive Mechanisms of Methionyl-Methionine in Lipopolysaccharide-Induced Inflammation in Bovine Mammary Epithelial Cell
by: Wei Lan, et al.
Published: (2021-03-01)